IMNM Immunome Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1472012 · Fiscal year ends 12/31
Financial factors as of 2026-03-31 (2026Q1), TTM = sum of the last four quarters
Growth
TTM revenue YoY-63.3%
TTM net income YoY-9.5%
TTM EPS YoY20.6%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-5,947.9%
Net margin-5,593.8%
FCF margin-5,118.9%
EBITDA margin-5,886.7%
Returns
ROE-50.1%
ROA-46.7%
ROIC (approx.)-679.8%
Asset turnover0.01x
Leverage & solvency
Liabilities / assets5.0%
Debt / equity0.00x
Current ratio21.68x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.87x
Accruals ratio-5.8%
Payout ratio—
Capex / revenue224.7%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $6.94M | $9.04M |
| R&D expense | $177.29M | $129.54M |
| SG&A expense | $43.77M | $32.95M |
| Operating income | -$224.11M | -$305.80M |
| Income tax | $0 | $0 |
| Net income | -$212.39M | -$292.96M |
| EBITDA | -$221.65M | -$304.23M |
| EPS (basic) | -2.43 | -5.00 |
| EPS (diluted) | -2.43 | -5.00 |
| Weighted avg. shares (diluted) | 87.35M | 58.64M |
| Banking | ||
| Net interest income | $11.72M | $12.84M |
| Balance sheet | ||
| Cash & equivalents | $653.48M | $143.45M |
| Short-term investments | $0 | $73.95M |
| Current assets | $660.78M | $221.34M |
| PP&E, net | $14.64M | $10.11M |
| Total assets | $683.19M | $240.24M |
| Current liabilities | $44.99M | $54.31M |
| Total liabilities | $48.84M | $59.08M |
| Shareholders' equity | $634.34M | $181.16M |
| Shares outstanding | 113.13M | 64.46M |
| Cash flow statement | ||
| Operating cash flow | -$190.92M | -$110.79M |
| Capital expenditure | $9.69M | $7.17M |
| Free cash flow | -$200.60M | -$117.97M |
| Investing cash flow | $60.80M | -$85.06M |
| Financing cash flow | $640.36M | $240.53M |
| Depreciation & amortization | $2.47M | $1.57M |
| Stock-based compensation | $25.69M | $15.75M |
Free plan shows the latest 2 periods; Pro shows all 7 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.